The Medical Journal of Australia · 2000 · 54 citations · 15 references
Veterinary MedicineHealth SciencesInfectious DiseasesDisease SurveillanceEpidemiologyPediatric Infectious DiseasesBacterial EpidemiologyBacterial InfectionsDisease EpidemiologyDisease Risk AssessmentInfectious Disease PreventionInfectious Disease Risk FactorsChildhood Pneumonia EpidemiologyEpidemiology Of Bacterial InfectionsIndigenous Child HealthIndigenous EpidemiologyInfection Risk FactorsInfectious Disease Morbidity PatternsLaboratory SurveillancePneumococcal Disease
OBJECTIVE: To examine the epidemiology of invasive pneumococcal disease (IPD) in the Northern Territory of Australia as a basis for optimising vaccination and healthcare provision. DESIGN: Prospective laboratory surveillance, with information collected from hospital and clinic records. SETTING: Northern Territory (NT) and rural communities in north-west South Australia served by an NT hospital, 1994-1998 (NT population is 27% Indigenous). MAIN OUTCOME MEASURES: IPD incidence and mortality, risk factors, clinical presentation and disease-causing serotypes in Indigenous and non-Indigenous people. RESULTS: 425 cases of IPD were detected, with 77% in Indigenous people. IPD incidence was highest in Indigenous children aged < 2 years (1534 per 100,000 in central Australia), but about 100 per 100,000 in non-Indigenous children < 2 years and all Indigenous age groups aged > or = 15 years. Mean ages of those with disease were 39 years in Indigenous people and 48 years in non-Indigenous people (P = 0.006) and, of those who died, 41 and 53 years, respectively (P = 0.04). IPD risk factors were present in 72% of Indigenous and 55% of non-Indigenous patients aged > or = 2 years. Serotype results for 363 isolates showed that the 23-valent vaccine covered 68% and 85% of isolates from Indigenous and non-Indigenous people aged > or = 2 years, respectively, while the proposed seven-, nine- and 11-valent conjugate vaccines covered 58%, 66% and 67% of isolates, respectively, from Indigenous children aged < 2 years and 72% each of those from non-Indigenous children. Case-fatality rates were 10% in both Indigenous and non-Indigenous people. CONCLUSION: These data support the recent change in NT vaccination policy which extended funding for the 23-valent vaccine to all Indigenous people aged > or = 15 years and all Indigenous children in central Australia aged 2-5 years. The high rates of IPD in both Indigenous and non-Indigenous children mandate action to make conjugate vaccine available as soon as possible.
15
The Australian Immunisation Handbook
Andrea Bradford · Australian Infection Control · 2000 · 907 citations
Pneumococcal Polysaccharide Vaccine Efficacy
Jay C. Butler · JAMA · 1993 · 634 citations
Veterinary Medicine, Infectious Diseases, Preventive Medicine +17